Browsing Tag
OCU410
3 posts
Can Ocugen, Inc. disrupt chronic eye injections with a single gene therapy procedure? (NASDAQ: OCGN)
Ocugen, Inc. reports Phase 2 gene therapy results that could reshape retinal treatment economics. Discover what this means for investors and competitors.
Positive early Phase 2 data strengthen Ocugen’s case for OCU410 in the fast-evolving dry AMD treatment market
Find out how Ocugen’s early Phase 2 data for OCU410 could reshape competition and investor sentiment in the fast-growing dry AMD treatment market.
Ocugen reports promising interim results for OCU410 clinical trial in geographic atrophy
Ocugen, Inc. has taken a significant step forward in the fight against geographic atrophy (GA) secondary to dry…